Navigation Links
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Date:11/19/2007

Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute

Renal Failure

FREMONT, Calif., Nov. 19 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it has commenced systemic dosing in humans of its proprietary product candidate, AKIi-5, a siRNA compound discovered and developed by Quark for the treatment of Acute Renal Failure (ARF), also called Acute Kidney Injury (AKI). Based on publicly available information, Quark believes that this is the first human clinical trial involving the systemic delivery of siRNA.

The Phase I clinical trial is a multi-center, double-blind, placebo controlled, dose-escalation trial assessing the safety and pharmacokinetics of AKIi-5 administered intravenously as a single dose to patients undergoing major cardiac surgery. Patients will be enrolled in the trial in a number of centers in the United States, Europe and Israel. Quark expects to complete the trial in early 2008. Depending on the results of this trial, Quark expects to initiate a dose-ranging Phase II clinical trial measuring AKIi-5 clinical activity.

Daniel Zurr, Chief Executive Officer, commented, "The initiation of human dosing in our Phase I trial in ARF signifies a very important step in Quark's clinical program and marks an important milestone in the RNAi industry. For Quark, the trial serves to further validate the strength of our pipeline and our overall expertise in the RNAi arena. With AKIi-5 now in the clinic, RTP801i-14, which we licensed to Pfizer, in a Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration, AHLi-11 in IND-enabling studies and additional RNAi-based candidate drugs in pre-clinical testing, we believe Quark has one of the most robust RNAi product portfolios in the industry.

"For the RNAi industry, the trial m
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...   LabStyle Innovations Corp . (OTCQB:DRIO), developer of ... appointment of Professor Richard B. Stone ... Directors. Prof. Stone brings over forty-five ... as an entrepreneur, venture capitalist public, company officer ... He currently serves on the board of directors ...
(Date:1/15/2014)... Jan. 15, 2014 Most osteoporosis patients want a ... recent online survey* sponsored by Mission Pharmacal Company. The ... Osteoporosis Foundation online support community, revealed that 74 percent ... comes in a form other than a pill or ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Reportlinker.com announces that a new market research ... Advanced Drug Delivery Markets (Liposomes, Polymers and ... Drug delivery is evolving at a ... discovered frequently. Advanced drug delivery deals with developing ...
... Jan. 11, 2011 Reportlinker.com announces that a ... catalogue: France Pharmaceutical Market Overview ... http://www.reportlinker.com/p0360215/France-Pharmaceutical-Market-Overview-–--Austerity-measures-will-impact-pharmaceutical-market-growth.html ... pharma market in France was valued at $38.8bn ...
Cached Medicine Technology:Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3Reportlinker Adds France Pharmaceutical Market Overview - Austerity measures will impact pharmaceutical market growth 2
(Date:7/11/2014)... 2014 Alliance for Cancer Gene ... dedicated exclusively to cell and gene therapies for ... joined the organization as Senior Development Officer. , ... experience securing gifts and addressing influential donors. Prior ... Director for NewYork Presbyterian Hospital/Columbia University Medical Center, ...
(Date:7/11/2014)... As reported by the New York Times ... number of severe adverse events such as renal failure, ... from the highly-promoted and costly immune-system drug, Acthar, have ... , a regulatory filing revealed that the total number ... 14% of prescriptions, up from 9.1% in 2011. Specifically, ...
(Date:7/11/2014)... surgery to repair damage to the anterior cruciate ligament (ACL) ... -- could increase a young athlete,s risk for further injuries, ... patients, aged 8 to 16, who had ACL reconstruction surgery. ... after their injury, 37 had surgery six to 12 weeks ... after their injury. The youngsters who had surgery later ...
(Date:7/11/2014)... 2014 Riverside Health System became the first ... Virginia in late 2012 and now, in partnership with Williamsburg ... throughout the Williamsburg and Newport News region. , Also known ... benefits to independent older adults who wish to remain in ... net of continuing care services as well as control over ...
(Date:7/11/2014)... unravel mechanisms that guide function and differentiation of blood ... including our immune system. The study of human blood ... found in the bone marrow in specialized "niches" that ... group of scientists from Dresden led by stem cell ... to generate a mouse model that supports the transplantation ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Opening-up the stem cell niche 2
... and ISMANING, Germany, Oct. 17 /PRNewswire-FirstCall/,-- XIRING ... security solutions,for remote transactions, and SCM Microsystems ... of solutions that open the Digital,World, today ... eHealth,smart card terminals for the new generation ...
... today filed an amicus brief on behalf of ten ... RU-486., AUL President Dr. Charmaine Yoest stated, "RU-486 ... women,s lives. We must put a stop to,abortionists, dangerous, ... in the right direction, and as we argue in ...
... into any grocery store,and there,s likely to be ... struggle with mindless eating have already begun to ... people find that Halloween spurs,a particularly tough time ... coming, it,only becomes more challenging. Dieters, mindless eaters, ...
... SPRINGFIELD, Mass., Oct. 16 With a combination ... become its hallmark, Massachusetts Mutual Life Insurance Company,(MassMutual) ... to the cause,of Breast Cancer Awareness Month., ... contribute tens of thousands,of dollars to cancer research, ...
... Alert Urges HR/Leadership Development to Implement Post-Crash Development Programs with ... ... Gainesville, FL (PRWEB) October 16, 2008 -- ... and how human resources and leadership development can quickly ...
... researcher, clinical nutritionist and women,s health practitioner, has ... Revitalizer, designed to bring back thicker, fuller hair ... Nails Revitalizer is available exclusively through Doctors, Preferred, ... one of the largest North American direct-mail supplement ...
Cached Medicine News:Health News:XIRING and SCM Microsystems Jointly Develop Mobile Terminals for German eHealth Market 2Health News:XIRING and SCM Microsystems Jointly Develop Mobile Terminals for German eHealth Market 3Health News:Ohio's Regulation of RU-486 Clear and Constitutional, Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 2Health News:A Mindful Chocolate Meditation 2Health News:Donations, Education, and People-Power Mark MassMutual Breast Cancer Awareness Month Efforts 2Health News:Donations, Education, and People-Power Mark MassMutual Breast Cancer Awareness Month Efforts 3Health News:Donations, Education, and People-Power Mark MassMutual Breast Cancer Awareness Month Efforts 4Health News:Perth Leadership Institute Issues Alert on the Post-Crash Environment Facing HR/Leadership Development 2Health News:Perth Leadership Institute Issues Alert on the Post-Crash Environment Facing HR/Leadership Development 3Health News:Dr. Lark Creates Nutritional Supplement to Restore Thick Hair and Strong Nails 2Health News:Dr. Lark Creates Nutritional Supplement to Restore Thick Hair and Strong Nails 3
... an innovative, quick and easy automated ... 60% less space on your laboratory ... this amazingly easy-to-use, one-hand system, you ... whole range of Diamond Tips. All ...
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
For the quantitative determination of luteinizing hormone (LH) concentration in human serum....
Medicine Products: